KR102827354B1 - 폐암의 검출 및 치료 방법 - Google Patents

폐암의 검출 및 치료 방법 Download PDF

Info

Publication number
KR102827354B1
KR102827354B1 KR1020247002923A KR20247002923A KR102827354B1 KR 102827354 B1 KR102827354 B1 KR 102827354B1 KR 1020247002923 A KR1020247002923 A KR 1020247002923A KR 20247002923 A KR20247002923 A KR 20247002923A KR 102827354 B1 KR102827354 B1 KR 102827354B1
Authority
KR
South Korea
Prior art keywords
ser
thr
pro
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247002923A
Other languages
English (en)
Korean (ko)
Other versions
KR20240015172A (ko
Inventor
사미르 한나쉬
아유무 다구치
지딩 펑
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20240015172A publication Critical patent/KR20240015172A/ko
Application granted granted Critical
Publication of KR102827354B1 publication Critical patent/KR102827354B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/57423—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Physiology (AREA)
  • Probability & Statistics with Applications (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Signal Processing (AREA)
  • Epidemiology (AREA)
  • Artificial Intelligence (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
KR1020247002923A 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법 Active KR102827354B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762456731P 2017-02-09 2017-02-09
US62/456,731 2017-02-09
KR1020197026040A KR102630885B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법
PCT/US2018/017704 WO2018148600A1 (en) 2017-02-09 2018-02-09 Methods for the detection and treatment of lung cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197026040A Division KR102630885B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법

Publications (2)

Publication Number Publication Date
KR20240015172A KR20240015172A (ko) 2024-02-02
KR102827354B1 true KR102827354B1 (ko) 2025-06-30

Family

ID=63107741

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247002923A Active KR102827354B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법
KR1020197026040A Active KR102630885B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197026040A Active KR102630885B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법

Country Status (8)

Country Link
US (3) US12504430B2 (https=)
EP (2) EP4528741A3 (https=)
JP (1) JP7311417B2 (https=)
KR (2) KR102827354B1 (https=)
CN (2) CN110291397A (https=)
CA (1) CA3053116A1 (https=)
ES (1) ES2995959T3 (https=)
WO (1) WO2018148600A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291397A (zh) 2017-02-09 2019-09-27 得克萨斯大学体系董事会 肺癌的检测和治疗方法
WO2021016711A1 (en) * 2019-07-29 2021-02-04 Biomark Cancer Systems Inc. Method of discriminating lung cancer patients
CA3165068A1 (en) 2020-01-30 2021-08-05 John E. Blume Lung biomarkers and methods of use thereof
EP4143578B1 (en) * 2020-04-28 2024-06-05 Luxembourg Institute of Health (LIH) Biomarkers for detection of lung cancer
WO2022051753A1 (en) * 2020-09-01 2022-03-10 Oncodea Corporation Predictive diagnostic test for early detection and monitoring of diseases
CN112147099A (zh) * 2020-09-22 2020-12-29 范庆坤 一种m蛋白紫外分光检测法
KR20230080442A (ko) * 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료를 위한 방법
EP4237090B1 (en) * 2020-10-29 2026-02-18 Board of Regents, The University of Texas System Methods for the detection and treatment of ovarian cancer
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
US12334190B2 (en) 2021-03-31 2025-06-17 PrognomIQ, Inc. Multi-omic assessment using proteins and nucleic acids
GB2607436A (en) * 2021-03-31 2022-12-07 Prognomiq Inc Multi-omic assessment
CN113267587B (zh) * 2021-05-27 2023-11-10 杭州广科安德生物科技有限公司 测定pro-SFTPB标准物质含量的特征肽段及方法
US12387508B2 (en) 2021-09-10 2025-08-12 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
US12007397B2 (en) 2021-09-13 2024-06-11 PrognomIQ, Inc. Enhanced detection and quantitation of biomolecules
WO2023209218A1 (en) * 2022-04-28 2023-11-02 Janssen Pharmaceutica Nv Metabolite predictors for lung cancer
EP4357782A1 (en) * 2022-10-18 2024-04-24 MU Bioteknik Aktiebolag Protein biomarker panel for the diagnosis of colorectal cancer
CN115575636B (zh) * 2022-11-22 2023-04-04 杭州广科安德生物科技有限公司 一种用于肺癌检测的生物标志物及其系统
CN116593702B (zh) * 2023-05-11 2024-04-05 杭州广科安德生物科技有限公司 一种肺癌的生物标志物以及诊断系统
WO2025064345A2 (en) * 2023-09-22 2025-03-27 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
CN118983078B (zh) * 2024-08-15 2025-03-25 立本医疗器械(成都)有限公司 基于ptr-tof-ms的肺癌筛查模型构建方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144034A1 (en) 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
WO2011140234A1 (en) 2010-05-07 2011-11-10 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
US20130196868A1 (en) 2011-12-18 2013-08-01 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
US20140274772A1 (en) 2013-03-15 2014-09-18 Rush University Medical Center Biomarker panel for detecting lung cancer
US20140271453A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
US20160060329A1 (en) 2014-07-28 2016-03-03 Donald SIN Compositions and methods for the diagnosis and prognosis of lung cancer
JP2016176954A (ja) * 2005-12-22 2016-10-06 アボツト・モレキユラー・インコーポレイテツド 肺がんへの傾向についてのスクリーニングのための方法およびマーカー組合せ

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20080133141A1 (en) * 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20120087860A1 (en) * 2010-05-24 2012-04-12 Marek Malecki Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags
WO2011150974A1 (en) 2010-06-03 2011-12-08 Porto Conte Ricerche S.R.L. Biomarkers for lung neuroendocrine tumors
CN102321760A (zh) * 2011-08-26 2012-01-18 泸州医学院附属医院 一种非小细胞肺癌标志物及应用
WO2013154998A1 (en) 2012-04-09 2013-10-17 Duke University Serum biomarkers and pulmonary nodule size for the early detection of lung cancer
CA3198282A1 (en) * 2015-06-26 2016-12-29 Biomark Cancer Systems Inc. Method of detecting lung cancer
EP3427051B1 (en) 2016-03-08 2021-06-16 Magarray, Inc. Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer
CN105717146B (zh) * 2016-03-29 2018-11-09 复旦大学附属中山医院 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒
CN109478231A (zh) 2016-04-01 2019-03-15 20/20基因系统股份有限公司 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物
EP3361256A1 (en) 2017-02-08 2018-08-15 Fundación para la Investigación Médica Aplicada In vitro method for the diagnosis of lung cancer
CN110291397A (zh) 2017-02-09 2019-09-27 得克萨斯大学体系董事会 肺癌的检测和治疗方法
IL319255A (en) 2017-08-07 2025-04-01 Univ Johns Hopkins Methods and materials for cancer assessment and treatment
KR20230080442A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료를 위한 방법
WO2024107923A1 (en) 2022-11-17 2024-05-23 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
TR2022022101A2 (tr) 2022-12-31 2023-04-24 Atatuerk Ueniversitesi Fikri Muelkiyet Haklari Koordinatoerluegue Doener Sermaye Isletmesi Nemlendi̇ri̇ci̇ modelaj örtüsü
EP4721103A2 (en) 2023-05-31 2026-04-08 Board of Regents, The University of Texas System Methods for the detection and treatment of lung cancer
WO2025064345A2 (en) 2023-09-22 2025-03-27 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016176954A (ja) * 2005-12-22 2016-10-06 アボツト・モレキユラー・インコーポレイテツド 肺がんへの傾向についてのスクリーニングのための方法およびマーカー組合せ
WO2008144034A1 (en) 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
WO2011140234A1 (en) 2010-05-07 2011-11-10 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
US20130196868A1 (en) 2011-12-18 2013-08-01 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
US20140271453A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
US20140274772A1 (en) 2013-03-15 2014-09-18 Rush University Medical Center Biomarker panel for detecting lung cancer
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
US20160060329A1 (en) 2014-07-28 2016-03-03 Donald SIN Compositions and methods for the diagnosis and prognosis of lung cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Don D Sin et al, Journal of Clinical Oncology (2013.12.20.), vol 31, no 36, pp 4536-4543.
William R Wikoff et al, Journal of Clinical Oncology (2015.11.20.), vol 33, no 33, pp 3880-3886.

Also Published As

Publication number Publication date
EP3580560A1 (en) 2019-12-18
CN117368475A (zh) 2024-01-09
WO2018148600A1 (en) 2018-08-16
EP4528741A3 (en) 2025-04-09
CA3053116A1 (en) 2018-08-16
KR20240015172A (ko) 2024-02-02
ES2995959T3 (en) 2025-02-11
US12504430B2 (en) 2025-12-23
CN110291397A (zh) 2019-09-27
EP4528741A2 (en) 2025-03-26
JP7311417B2 (ja) 2023-07-19
US20200025766A1 (en) 2020-01-23
KR102630885B1 (ko) 2024-01-29
KR20190116368A (ko) 2019-10-14
US20260063638A1 (en) 2026-03-05
US20230314436A1 (en) 2023-10-05
EP3580560A4 (en) 2020-12-09
JP2020510816A (ja) 2020-04-09
EP3580560B1 (en) 2024-10-02
US12405274B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
KR102827354B1 (ko) 폐암의 검출 및 치료 방법
Zhang et al. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients
US20240159753A1 (en) Methods for the detection and treatment of lung cancer
Lycke et al. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics
Nagy Jr et al. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer
Di Noia et al. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
He et al. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
CN108369233B (zh) 基于标志物人附睾蛋白4 (he4)检测肺腺癌的复发的方法及相关用途
Reix et al. A novel machine learning-derived decision tree including uPA/PAI-1 for breast cancer care
KR20260030760A (ko) 폐암의 검출 및 치료 방법
Jannawan et al. High level of serum coiled-coil domain containing 25 (CCDC25) as a diagnostic marker for cholangiocarcinoma but not for other cancers
Xiong et al. Protein expression profiling identifies a prognostic model for ovarian cancer
Tcherkassova et al. Diagnostic significance of the novel biomarker combination for early-stage non-small cell lung cancer detection: results of the blind clinical study
EP4413372A1 (en) Lung cancer prediction and uses thereof
HK40105704A (zh) 肺癌的检测和治疗方法
Tahanovich et al. Blood laboratory parameters can predict relapse-free survival of patients with advanced squamous cell lung cancer and adenocarcinoma
CN116529603A (zh) 用于检测和治疗肺癌的方法
HK1259002B (en) Methods of detecting a relapse of a lung adenocarcinoma based on marker human epididymis protein 4 (he4) and related uses

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000